Physician profile
Laura E Rosenfield
NPI 1215198783
$1,323.61
in general payments reported to CMS, 2019-2025
25 companies · $109 in 2025
The $109 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $221 · 2020: $16.66 · 2021: $54.74 · 2022: $189 · 2023: $312 · 2024: $422 · 2025: $109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $843.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $842.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $184.03 | 2019-2024 | Lo Loestrin Fe, Liletta |
| Organon LLC | $181.37 | 2022-2025 | Nexplanon |
| Shield Therapeutics INC | $127.30 | 2023-2024 | Accrufer |
| Hologic Sales and Service, LLC | $81.69 | 2019-2024 | Myosure Tissue Removal Device, Thinprep 2000 Processor |
| Pfizer INC. | $79.27 | 2021-2024 | |
| Exeltis, USA INC. | $79.12 | 2019-2025 | Slynd |
| Bayer Healthcare Pharmaceuticals INC. | $63.27 | 2019-2023 | |
| Astellas Pharma US INC | $57.53 | 2022-2023 | Veozah |
| Mayne Pharma Commercial LLC | $51.52 | 2023 | |
| Dexcom, INC. | $46.64 | 2024-2025 | Dexcom G6 Transmitter |
| Millicent US INC | $43.04 | 2023-2024 | Intrarosa, Femring |
| Merck Sharp & Dohme LLC | $40.09 | 2019-2022 | |
| Evofem Biosciences, INC. | $37.78 | 2022 | |
| Sage Therapeutics, LLC | $37.05 | 2024 | |
| Duchesnay USA Incorporated | $29.28 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $28.20 | 2019 | |
| Ethicon US, LLC | $25.57 | 2024 | Surgicel Nu-Knit, Enseal X1 |
| Sumitomo Pharma America, INC. | $25.15 | 2024 | Myfembree |
| Molnlycke Health Care US, LLC | $19.60 | 2024 | Mepilex Border Post-Op Ag, Avance |
| Medtronic, INC. | $18.47 | 2024 | Ligasure |
| Therapeuticsmd, INC. | $17.37 | 2021 | |
| Lilly USA, LLC | $15.01 | 2025 | Zepbound, Mounjaro |
| Amag Pharmaceuticals, INC. | $13.49 | 2019 | |
| Novo Nordisk INC | $11.16 | 2019 | |
| Channel Medsystems, INC. | $10.61 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Rosenfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.